DE69636055T2 - Adenovirale vektoren, die nicht von gruppe c adenovirus typen abgeleitet sind - Google Patents
Adenovirale vektoren, die nicht von gruppe c adenovirus typen abgeleitet sind Download PDFInfo
- Publication number
- DE69636055T2 DE69636055T2 DE69636055T DE69636055T DE69636055T2 DE 69636055 T2 DE69636055 T2 DE 69636055T2 DE 69636055 T DE69636055 T DE 69636055T DE 69636055 T DE69636055 T DE 69636055T DE 69636055 T2 DE69636055 T2 DE 69636055T2
- Authority
- DE
- Germany
- Prior art keywords
- vector
- adenovirus
- group
- region
- deficient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Revoked
Links
- 239000013598 vector Substances 0.000 title claims abstract description 124
- 241000701161 unidentified adenovirus Species 0.000 title claims description 111
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 52
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 49
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 49
- 230000002950 deficient Effects 0.000 claims abstract description 41
- 230000010076 replication Effects 0.000 claims abstract description 27
- 238000001415 gene therapy Methods 0.000 claims abstract description 23
- 238000002255 vaccination Methods 0.000 claims abstract description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 69
- 238000000034 method Methods 0.000 claims description 35
- 230000014509 gene expression Effects 0.000 claims description 33
- 241000700605 Viruses Species 0.000 claims description 27
- 238000012546 transfer Methods 0.000 claims description 14
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 230000000295 complement effect Effects 0.000 claims description 8
- 230000029812 viral genome replication Effects 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- 238000012360 testing method Methods 0.000 claims description 5
- 230000001225 therapeutic effect Effects 0.000 claims description 5
- 231100000419 toxicity Toxicity 0.000 claims description 5
- 230000001988 toxicity Effects 0.000 claims description 5
- 241000282412 Homo Species 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 4
- 230000000069 prophylactic effect Effects 0.000 claims description 4
- 108700026244 Open Reading Frames Proteins 0.000 claims description 2
- 230000000644 propagated effect Effects 0.000 claims 1
- 230000001902 propagating effect Effects 0.000 claims 1
- 230000003362 replicative effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 87
- 108020004414 DNA Proteins 0.000 description 42
- 239000012634 fragment Substances 0.000 description 33
- 230000003612 virological effect Effects 0.000 description 24
- 230000006870 function Effects 0.000 description 17
- 239000006166 lysate Substances 0.000 description 16
- 239000000203 mixture Substances 0.000 description 16
- 239000013612 plasmid Substances 0.000 description 16
- 230000004543 DNA replication Effects 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- 108020005202 Viral DNA Proteins 0.000 description 14
- 229920001184 polypeptide Polymers 0.000 description 13
- 102000004196 processed proteins & peptides Human genes 0.000 description 13
- 108090000765 processed proteins & peptides Proteins 0.000 description 13
- 238000009472 formulation Methods 0.000 description 11
- 238000005215 recombination Methods 0.000 description 11
- 230000006798 recombination Effects 0.000 description 11
- 238000001890 transfection Methods 0.000 description 11
- 230000007812 deficiency Effects 0.000 description 10
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 9
- 229930006000 Sucrose Natural products 0.000 description 9
- 210000000234 capsid Anatomy 0.000 description 9
- 229960004793 sucrose Drugs 0.000 description 9
- 108091028043 Nucleic acid sequence Proteins 0.000 description 8
- 238000009396 hybridization Methods 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 230000002068 genetic effect Effects 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 239000005720 sucrose Substances 0.000 description 7
- 241000220479 Acacia Species 0.000 description 6
- 101150075174 E1B gene Proteins 0.000 description 6
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 6
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 6
- 238000012217 deletion Methods 0.000 description 6
- 230000037430 deletion Effects 0.000 description 6
- 230000001939 inductive effect Effects 0.000 description 6
- 238000003780 insertion Methods 0.000 description 6
- 230000037431 insertion Effects 0.000 description 6
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 5
- 201000003883 Cystic fibrosis Diseases 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 239000013543 active substance Substances 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000000835 fiber Substances 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 238000003752 polymerase chain reaction Methods 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- CXURGFRDGROIKG-UHFFFAOYSA-N 3,3-bis(chloromethyl)oxetane Chemical compound ClCC1(CCl)COC1 CXURGFRDGROIKG-UHFFFAOYSA-N 0.000 description 4
- 206010001258 Adenoviral infections Diseases 0.000 description 4
- 101710164463 Preterminal protein Proteins 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 238000004806 packaging method and process Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 230000006820 DNA synthesis Effects 0.000 description 3
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000001502 gel electrophoresis Methods 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 239000013615 primer Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 239000013603 viral vector Substances 0.000 description 3
- 210000002845 virion Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- NCMVOABPESMRCP-SHYZEUOFSA-N 2'-deoxycytosine 5'-monophosphate Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)C1 NCMVOABPESMRCP-SHYZEUOFSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108090000565 Capsid Proteins Proteins 0.000 description 2
- 102100023321 Ceruloplasmin Human genes 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 241000557626 Corvus corax Species 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 101710096438 DNA-binding protein Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 239000001828 Gelatine Substances 0.000 description 2
- 241000598171 Human adenovirus sp. Species 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 108091034057 RNA (poly(A)) Proteins 0.000 description 2
- 101710184528 Scaffolding protein Proteins 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 101150055766 cat gene Proteins 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000000120 cytopathologic effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 235000013681 dietary sucrose Nutrition 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 210000001533 respiratory mucosa Anatomy 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 229920002477 rna polymer Polymers 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000002123 temporal effect Effects 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 241000701242 Adenoviridae Species 0.000 description 1
- 208000010370 Adenoviridae Infections Diseases 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 102000005853 Clathrin Human genes 0.000 description 1
- 108010019874 Clathrin Proteins 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 101710116602 DNA-Binding protein G5P Proteins 0.000 description 1
- 238000007900 DNA-DNA hybridization Methods 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 101710183861 Hexon-associated protein Proteins 0.000 description 1
- 101710155188 Hexon-interlacing protein Proteins 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 108010047956 Nucleosomes Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 101710193132 Pre-hexon-linking protein VIII Proteins 0.000 description 1
- 101710143509 Pre-histone-like nucleoprotein Proteins 0.000 description 1
- 101710111548 Pre-protein VI Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 101710162453 Replication factor A Proteins 0.000 description 1
- 101710176758 Replication protein A 70 kDa DNA-binding subunit Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 101710176276 SSB protein Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 101710126859 Single-stranded DNA-binding protein Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 108091027544 Subgenomic mRNA Proteins 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 210000002534 adenoid Anatomy 0.000 description 1
- 108700010877 adenoviridae proteins Proteins 0.000 description 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229930193282 clathrin Natural products 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 210000004492 nuclear pore Anatomy 0.000 description 1
- 210000001623 nucleosome Anatomy 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 235000015205 orange juice Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 238000012868 site-directed mutagenesis technique Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 210000003956 transport vesicle Anatomy 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 238000005829 trimerization reaction Methods 0.000 description 1
- 238000009966 trimming Methods 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000006648 viral gene expression Effects 0.000 description 1
- 230000009447 viral pathogenesis Effects 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
- 230000010464 virion assembly Effects 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Plant Pathology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/537,402 US5837511A (en) | 1995-10-02 | 1995-10-02 | Non-group C adenoviral vectors |
| US537402 | 1995-10-02 | ||
| PCT/US1996/015274 WO1997012986A2 (en) | 1995-10-02 | 1996-09-24 | Non-group c adenoviral vectors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69636055D1 DE69636055D1 (de) | 2006-05-24 |
| DE69636055T2 true DE69636055T2 (de) | 2007-04-12 |
Family
ID=24142494
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69636055T Revoked DE69636055T2 (de) | 1995-10-02 | 1996-09-24 | Adenovirale vektoren, die nicht von gruppe c adenovirus typen abgeleitet sind |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US5837511A (enExample) |
| EP (1) | EP0866873B1 (enExample) |
| JP (2) | JPH11514866A (enExample) |
| AT (1) | ATE323773T1 (enExample) |
| DE (1) | DE69636055T2 (enExample) |
| WO (1) | WO1997012986A2 (enExample) |
Families Citing this family (162)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2705686B1 (fr) * | 1993-05-28 | 1995-08-18 | Transgene Sa | Nouveaux adénovirus défectifs et lignées de complémentation correspondantes. |
| DE69533295T3 (de) * | 1994-02-16 | 2009-07-16 | The Government Of The United States Of America, As Represented By The Secretary, The Department Of Health And Human Services | Melanoma-assoziierte Antigene, Epitope davon und Impstoffe gegen Melanoma |
| US6265212B1 (en) | 1995-06-15 | 2001-07-24 | Introgene B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
| KR100470180B1 (ko) | 1995-06-15 | 2005-02-04 | 크루셀 홀란드 비.브이. | 유전자 요법에 사용할 수 있는 인간의 재조합아데노바이러스 패키징 시스템 |
| US6783980B2 (en) * | 1995-06-15 | 2004-08-31 | Crucell Holland B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
| US20020068049A1 (en) * | 1998-09-10 | 2002-06-06 | Henderson Daniel R. | Tissue specific adenoviral vectors |
| US20040156861A1 (en) * | 1996-07-11 | 2004-08-12 | Figdor Carl Gustav | Melanoma associated peptide analogues and vaccines against melanoma |
| US5877011A (en) * | 1996-11-20 | 1999-03-02 | Genzyme Corporation | Chimeric adenoviral vectors |
| US5849561A (en) * | 1997-05-22 | 1998-12-15 | Cornell Research Foundation, Inc. | Method for the production of non-group C adenoviral vectors |
| US6696423B1 (en) | 1997-08-29 | 2004-02-24 | Biogen, Inc. | Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta |
| US20040204381A1 (en) * | 1997-11-12 | 2004-10-14 | Moskal Joseph R | Detection and treatment of glyco-enzyme-related disease |
| US6670188B1 (en) | 1998-04-24 | 2003-12-30 | Crucell Holland B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
| AU4070499A (en) * | 1998-04-30 | 1999-11-16 | Cornell Research Foundation Inc. | Adenoviral vectors with tandem fiber proteins |
| US6413776B1 (en) | 1998-06-12 | 2002-07-02 | Galapagos Geonomics N.V. | High throughput screening of gene function using adenoviral libraries for functional genomics applications |
| US20030017138A1 (en) * | 1998-07-08 | 2003-01-23 | Menzo Havenga | Chimeric adenoviruses |
| US20040043489A1 (en) * | 1998-07-08 | 2004-03-04 | Menzo Havenga | Gene delivery vectors provided with a tissue tropism for dendritic cells and methods of use |
| CA2340276A1 (en) | 1998-08-28 | 2000-03-09 | Duke University | Adenoviruses deleted in the iva2, 100k and/or preterminal protein sequences |
| US6929946B1 (en) * | 1998-11-20 | 2005-08-16 | Crucell Holland B.V. | Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells |
| US6224566B1 (en) | 1999-05-04 | 2001-05-01 | Cardiodyne, Inc. | Method and devices for creating a trap for confining therapeutic drugs and/or genes in the myocardium |
| ES2372823T3 (es) * | 1999-05-17 | 2012-01-26 | Crucell Holland B.V. | Adenovirus recombinante del serotipo ad11. |
| US6492169B1 (en) * | 1999-05-18 | 2002-12-10 | Crucell Holland, B.V. | Complementing cell lines |
| US20050232900A1 (en) * | 1999-05-18 | 2005-10-20 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
| US6913922B1 (en) * | 1999-05-18 | 2005-07-05 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
| EP1157999A1 (en) * | 2000-05-24 | 2001-11-28 | Introgene B.V. | Methods and means for enhancing skin transplantation using gene delivery vehicles having tropism for primary fibroblasts, as well as other uses thereof |
| EP1322774A2 (en) * | 2000-09-20 | 2003-07-02 | Crucell Holland B.V. | Gene delivery vectors provided with a tissue tropism for dendritic cells |
| DE60138403D1 (de) * | 2000-09-26 | 2009-05-28 | Crucell Holland Bv | Adenovirale vektoren für die übertragung von genen in zellen der skelettmuskulatur oder myoblasten |
| JP2004536572A (ja) * | 2001-02-23 | 2004-12-09 | セル・ジェネシス・インコーポレイテッド | 新規ベクター構築物 |
| AU2002332736A1 (en) * | 2001-08-30 | 2003-03-18 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of | New adenovirus type 7 vectors |
| EP1573035B1 (en) | 2002-02-22 | 2015-09-02 | The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services | Brother of the regulator of imprinted sites (boris) |
| PL215165B1 (pl) * | 2002-04-25 | 2013-10-31 | Crucell Holland Bv | Rekombinowany wektor adenowirusowy oraz sposób wytwarzania rekombinowanego wektora adenowirusowego |
| WO2004018627A2 (en) * | 2002-08-22 | 2004-03-04 | Merck & Co., Inc. | Methods for propagating adenovirus and virus produced thereby |
| US20040166091A1 (en) | 2003-02-24 | 2004-08-26 | Genvec, Inc. | Materials and methods for treating disorders of the ear |
| ES2391975T3 (es) * | 2003-07-25 | 2012-12-03 | Genvec, Inc. | Vacunas a base de vector adenovírico |
| EP2168603A1 (en) | 2003-11-14 | 2010-03-31 | GenVec, Inc. | Therapeutic regimen for treating cancer |
| NZ546983A (en) * | 2003-11-24 | 2009-05-31 | Canji Inc | Reduction of dermal scarring |
| ES2329607T3 (es) * | 2004-02-23 | 2009-11-27 | Crucell Holland B.V. | Metodos de purificacion de virus. |
| JP2007532656A (ja) | 2004-04-12 | 2007-11-15 | アメリカ合衆国 | アデノウイルスベクターを用いて免疫応答を誘導するための方法 |
| WO2006008468A2 (en) * | 2004-07-20 | 2006-01-26 | The University Of Warwick | Adenovirus vector and method to manipulate the adenovirus genome |
| JP2008511336A (ja) * | 2004-09-01 | 2008-04-17 | アメリカ合衆国 | 免疫原性が増加したアデノウイルスベクターをインビボで用いる方法 |
| WO2006086357A2 (en) * | 2005-02-10 | 2006-08-17 | Merck & Co., Inc. | Adenovirus serotype 36 vectors, nucleic acid and viruses produced thereby |
| US8574595B2 (en) * | 2005-04-11 | 2013-11-05 | Crucell Holland B.V. | Virus purification using ultrafiltration |
| US9651543B2 (en) | 2005-08-31 | 2017-05-16 | The United States Of America As Represented By The Secretary Of The Navy | Malaria antigen screening method |
| US8450055B2 (en) * | 2005-08-31 | 2013-05-28 | The United States Of America As Represented By The Secretary Of The Navy | Malaria antigen screening method |
| AU2006284756B2 (en) * | 2005-08-31 | 2012-06-07 | Genvec, Inc. | Adenoviral vector-based malaria vaccines |
| CA2629163C (en) * | 2005-11-10 | 2017-03-21 | Genvec, Inc. | Adenoviral vector-based foot-and-mouth disease vaccine |
| US20080248060A1 (en) * | 2007-01-09 | 2008-10-09 | Genvec, Inc. | Adenoviral vector-based malaria vaccines |
| US20090202492A1 (en) * | 2008-01-25 | 2009-08-13 | University Of South Florida | Adenovirus vaccine utilizing ikk as adjuvant |
| US20110086063A1 (en) * | 2008-06-04 | 2011-04-14 | Cornell University | Vaccines for prevention and treatment of addiction |
| WO2010060719A1 (en) | 2008-11-03 | 2010-06-03 | Crucell Holland B.V. | Method for the production of adenoviral vectors |
| US9605844B2 (en) * | 2009-09-01 | 2017-03-28 | Cree, Inc. | Lighting device with heat dissipation elements |
| PL2488636T3 (pl) | 2009-10-15 | 2014-07-31 | Crucell Holland Bv | Sposób oczyszczania cząsteczek adenowirusów z hodowli o wysokim zagęszczeniu komórkowym |
| CN102575233B (zh) | 2009-10-15 | 2014-07-16 | 克鲁塞尔荷兰公司 | 从高细胞密度培养物纯化腺病毒的方法 |
| US20120219583A1 (en) | 2009-10-16 | 2012-08-30 | Los Alamos National Security, Llc | Nucleic acid sequences encoding expandable hiv mosaic proteins |
| PH12012500908A1 (en) | 2009-11-09 | 2017-08-23 | Genvec Inc | Methods of propagating monkey adenoviral vectors |
| WO2011057254A2 (en) | 2009-11-09 | 2011-05-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Simian adenoviral vector-based vaccines |
| KR101820980B1 (ko) | 2010-02-15 | 2018-01-22 | 얀센 백신스 앤드 프리벤션 비.브이. | Ａｄ 26 아데노바이러스 벡터를 제조하는 방법 |
| EP2547362B1 (en) | 2010-03-17 | 2021-08-25 | Cornell University | Disrupted adenovirus-based vaccine against drugs of abuse |
| US20130195800A1 (en) | 2010-03-23 | 2013-08-01 | Intrexon Corporation | Vectors Conditionally Expressing Therapeutic Proteins, Host Cells Comprising the Vectors, and Uses Thereof |
| WO2012021730A2 (en) | 2010-08-11 | 2012-02-16 | Genvec, Inc. | Respiratory syncytial virus (rsv) vaccine |
| CN103118702A (zh) | 2010-09-20 | 2013-05-22 | 克鲁塞尔荷兰公司 | 活动性结核病的治疗性接种 |
| MX354752B (es) | 2010-09-27 | 2018-03-20 | Janssen Vaccines & Prevention Bv | Regimen de vacunacion de sensibilizacion y refuerzo heterologo contra malaria. |
| WO2012083297A2 (en) | 2010-12-17 | 2012-06-21 | Genvec, Inc. | Adenoviral vectors with modified hexon regions |
| WO2012088041A1 (en) | 2010-12-20 | 2012-06-28 | Genvec, Inc. | Adenoviral vector-based dengue fever vaccine |
| US9402919B2 (en) | 2011-03-04 | 2016-08-02 | Intrexon Corporation | Vectors conditionally expressing protein |
| WO2012162428A1 (en) | 2011-05-23 | 2012-11-29 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Prime-boost vaccination for viral infection |
| BR112014008167B1 (pt) | 2011-10-05 | 2022-05-24 | Genvec Inc | Adenovírus ou vetor adenoviral e composição os compreendendo |
| EP2764014B1 (en) | 2011-10-05 | 2022-02-09 | GenVec, Inc. | Adenoviral vectors and methods of use |
| EP2764011B1 (en) | 2011-10-05 | 2021-04-07 | GenVec, Inc. | Adenoviral vector-based respiratory syncytial virus (rsv) vaccine |
| CN107937440A (zh) | 2011-10-05 | 2018-04-20 | 金维克有限公司 | 猴腺病毒(大猩猩)或腺病毒载体及其使用方法 |
| US20130122038A1 (en) | 2011-11-14 | 2013-05-16 | The United States Of America As Represented By The Secretary Of The Department | Heterologous prime-boost immunization using measles virus-based vaccines |
| EP2809346A1 (en) | 2012-02-02 | 2014-12-10 | GenVec, Inc. | Adenoviral vector-based malaria vaccine |
| SI2825640T1 (sl) | 2012-03-12 | 2016-08-31 | Crucell Holland B.V. | Šarže rekombinantnega adenovirusa s spremenjenimi konci |
| US8932607B2 (en) | 2012-03-12 | 2015-01-13 | Crucell Holland B.V. | Batches of recombinant adenovirus with altered terminal ends |
| US9125870B2 (en) | 2012-03-22 | 2015-09-08 | Crucell Holland B.V. | Vaccine against RSV |
| MY169352A (en) | 2012-03-22 | 2019-03-25 | Janssen Vaccines & Prevention Bv | Vaccine against rsv |
| US10004811B2 (en) | 2012-04-13 | 2018-06-26 | Cornell University | Development of a highly efficient second generation nicotine-conjugate vaccine to treat nicotine addiction |
| WO2013180967A1 (en) | 2012-05-29 | 2013-12-05 | Genvec, Inc. | Herpes simplex virus vaccine |
| WO2013181128A1 (en) | 2012-05-29 | 2013-12-05 | Genvec, Inc. | Modified serotype 28 adenoviral vectors |
| PT2970398T (pt) | 2013-03-13 | 2024-06-07 | The Us Secretary Department Ofhealth And Human Servic | Proteínas f de pré-fusão do vsr e sua utilização |
| AU2014259474B2 (en) | 2013-04-25 | 2018-09-13 | Janssen Vaccines & Prevention B.V. | Stabilized soluble prefusion RSV F polypeptides |
| CN105408348B (zh) | 2013-06-17 | 2021-07-06 | 扬森疫苗与预防公司 | 稳定化的可溶性融合前rsv f多肽 |
| CN105530917B (zh) | 2013-09-19 | 2020-06-05 | 扬森疫苗与预防公司 | 改进的腺病毒配制品 |
| WO2016037154A1 (en) | 2014-09-04 | 2016-03-10 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Recombinant hiv-1 envelope proteins and their use |
| WO2016037164A1 (en) | 2014-09-07 | 2016-03-10 | Selecta Biosciences, Inc. | Methods and compositions for attenuating gene expression modulating anti-viral transfer vector immune responses |
| TWI710635B (zh) | 2014-10-09 | 2020-11-21 | 美商珍維克公司 | 編碼人類無調同源物-1(hath1)之腺病毒載體 |
| AU2015341926B2 (en) | 2014-11-04 | 2018-09-27 | Vidamune B.V. | Therapeutic HPV16 vaccines |
| US10420834B2 (en) | 2014-12-24 | 2019-09-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Recombinant metapneumovirus F proteins and their use |
| ES3058017T3 (en) | 2015-01-20 | 2026-03-06 | Us Health | Recombinant human/bovine parainfluenza virus 3 (b/hpiv3) expressing a chimeric rsv/bpiv3 f protein and uses thereof |
| US10301377B2 (en) | 2015-02-24 | 2019-05-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use |
| WO2016146844A1 (en) | 2015-03-18 | 2016-09-22 | Janssen Vaccines & Prevention B.V. | Assays for recombinant expression systems |
| CA2981841A1 (en) | 2015-04-14 | 2016-10-20 | Janssen Vaccines & Prevention B.V. | Recombinant adenovirus expressing two transgenes with a bidirectional promoter |
| CA2991002C (en) | 2015-07-07 | 2023-11-28 | Janssen Vaccines & Prevention B.V. | Vaccine against rsv |
| JP6840718B2 (ja) | 2015-07-07 | 2021-03-10 | ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． | 安定化された可溶性融合前ｒｓｖ ｆポリペプチド |
| BR112018003019A2 (pt) | 2015-08-20 | 2018-09-25 | Janssen Vaccines & Prevention Bv | vacinas terapêuticas contra hpv18 |
| US20180280519A1 (en) | 2015-10-06 | 2018-10-04 | Janssen Vaccines & Prevention B.V. | Methods for preventing plastic-induced degradation of biologicals |
| WO2017139392A1 (en) | 2016-02-08 | 2017-08-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Recombinant hiv-1 envelope proteins and their use |
| EP3426291A1 (en) | 2016-03-09 | 2019-01-16 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Recombinant hiv-1 envelope proteins and their use |
| KR102500970B1 (ko) | 2016-04-05 | 2023-02-17 | 얀센 백신스 앤드 프리벤션 비.브이. | Rsv에 대한 백신 |
| PT3439672T (pt) | 2016-04-05 | 2021-02-24 | Janssen Vaccines & Prevention Bv | Proteína f do rsv pré-fusão solúvel e estabilizada para uso na profilaxia de infeção por rsv |
| MX2018013340A (es) | 2016-05-02 | 2019-08-21 | Janssen Vaccines & Prevention Bv | Combinaciones de vacunas terapeuticas para el vph. |
| JP7046835B2 (ja) | 2016-05-12 | 2022-04-04 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | 強力でバランスのとれた双方向性プロモーター |
| KR102421049B1 (ko) | 2016-05-30 | 2022-07-15 | 얀센 백신스 앤드 프리벤션 비.브이. | 안정화된 융합-전 rsv f 단백질 |
| CN109312362B (zh) | 2016-06-20 | 2022-06-28 | 扬森疫苗与预防公司 | 有效和平衡的双向启动子 |
| US10744196B2 (en) | 2016-07-14 | 2020-08-18 | Janssen Vaccines & Prevention B.V. | HPV vaccines |
| CA3038968A1 (en) | 2016-09-30 | 2018-04-05 | Genvec, Inc. | Adenovectors for delivery of therapeutic genetic material into t cells |
| US11602559B2 (en) | 2016-10-03 | 2023-03-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | HIV-1 Env fusion peptide immunogens and their use |
| EP4599847A3 (en) | 2016-10-25 | 2025-11-12 | Trustees of Dartmouth College | Prefusion coronavirus spike proteins and their use |
| WO2018109220A2 (en) | 2016-12-16 | 2018-06-21 | Institute For Research In Biomedicine | Novel recombinant prefusion rsv f proteins and uses thereof |
| WO2018129268A1 (en) | 2017-01-07 | 2018-07-12 | Selecta Biosciences, Inc. | Patterned dosing of immunosuppressants coupled to synthetic nanocarriers |
| SG11201906271QA (en) | 2017-02-09 | 2019-08-27 | Janssen Vaccines & Prevention Bv | Potent and short promoter for expression of heterologous genes |
| US11235056B2 (en) | 2017-03-24 | 2022-02-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Glycan-masked engineered outer domains of HIV-1 gp120 and their use |
| BR112019019813A2 (pt) | 2017-03-30 | 2020-04-22 | The University Of Queensland | moléculas quiméricas e usos das mesmas |
| JP2020519663A (ja) | 2017-05-17 | 2020-07-02 | ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． | Ｒｓｖ感染に対する防御免疫を誘導するための方法及び組成物 |
| EP3687561A4 (en) | 2017-09-01 | 2021-06-09 | The Australian National University | "immunoregulatory molecules and uses therefor" |
| US11229695B2 (en) | 2017-09-15 | 2022-01-25 | Janssen Vaccines & Prevention B.V. | Method for the safe induction of immunity against RSV |
| MX2020003838A (es) | 2017-10-13 | 2020-08-06 | Selecta Biosciences Inc | Metodos y composiciones para atenuar las respuestas de inmunoglobulina m del vector de transferencia antiviral. |
| EP3697440A1 (en) | 2017-10-16 | 2020-08-26 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Recombinant hiv-1 envelope proteins and their use |
| JP7366014B2 (ja) | 2017-10-31 | 2023-10-20 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | アデノウイルス及びその用途 |
| EP3704256A1 (en) | 2017-10-31 | 2020-09-09 | Janssen Vaccines & Prevention B.V. | Adenovirus vectors and uses thereof |
| EP3704139A1 (en) | 2017-10-31 | 2020-09-09 | Janssen Vaccines & Prevention B.V. | Adenovirus and uses thereof |
| SG11202003200VA (en) | 2017-10-31 | 2020-05-28 | Janssen Vaccines & Prevention Bv | Adenovirus and uses thereof |
| PT3743106T (pt) | 2018-01-23 | 2022-08-24 | Janssen Vaccines & Prevention Bv | Vacinas contra o vírus da influenza e suas utilizações |
| KR20200139679A (ko) | 2018-02-26 | 2020-12-14 | 안톨알엑스, 인크. | 면역관용성 리포솜 및 그의 사용 방법 |
| US12404306B2 (en) | 2018-03-06 | 2025-09-02 | Precigen, Inc. | Human papillomavirus vaccines and uses of the same |
| IL277128B2 (en) | 2018-03-06 | 2025-11-01 | Precigen Inc | Hepatitis b vaccines and uses of the same |
| AU2019368218B2 (en) | 2018-10-22 | 2026-02-12 | New York University | Recombinant GP120 protein with V1-loop deletion |
| CN113164583A (zh) | 2018-11-13 | 2021-07-23 | 扬森疫苗与预防公司 | 稳定的融合前rsv f蛋白 |
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| MX2021012991A (es) | 2019-04-25 | 2021-12-10 | Janssen Vaccines & Prevention Bv | Antigenos de gripe recombinantes. |
| BR112021021566A2 (pt) | 2019-04-28 | 2022-04-19 | Selecta Biosciences Inc | Métodos para tratamento de indivíduos com imunidade preexistente a vetores de transferência viral |
| EP3969044A1 (en) | 2019-05-15 | 2022-03-23 | Janssen Vaccines & Prevention B.V. | Co-administration of seasonal influenza vaccine and an adenovirus based respiratory syncytial virus vaccine |
| US20220193219A1 (en) | 2019-05-15 | 2022-06-23 | Janssen Vaccines & Prevention B.V. | Prophylactic treatment of respiratory syncytial virus infection with an adenovirus based vaccine |
| BR112021023594A2 (pt) | 2019-05-28 | 2022-02-08 | Selecta Biosciences Inc | Métodos e composições para resposta imune de vetor de transferência antiviral atenuada |
| CA3152957A1 (en) | 2019-09-05 | 2021-03-11 | Janssen Vaccines & Prevention B.V. | Influenza virus vaccines and uses thereof |
| JP7711050B2 (ja) | 2019-10-03 | 2025-07-22 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | アデノウイルスベクターおよびその使用 |
| JP7640538B2 (ja) | 2019-10-08 | 2025-03-05 | トラスティーズ オブ ボストン カレッジ | 複数の異なる非天然アミノ酸を含有するタンパク質、並びにそのようなタンパク質の製造方法及び使用方法 |
| CN114980920A (zh) | 2019-11-18 | 2022-08-30 | 詹森生物科技公司 | 基于突变体calr和jak2的疫苗及其用途 |
| CN114981298B (zh) | 2019-12-12 | 2024-08-20 | 听治疗有限责任公司 | 用于预防和治疗听力损失的组合物和方法 |
| MX2022009836A (es) | 2020-02-11 | 2022-11-30 | Us Health | Vacuna para sars-cov-2. |
| TW202144388A (zh) | 2020-02-14 | 2021-12-01 | 美商健生生物科技公司 | 在卵巢癌中表現之新抗原及其用途 |
| TW202144389A (zh) | 2020-02-14 | 2021-12-01 | 美商健生生物科技公司 | 在多發性骨髓瘤中表現之新抗原及其用途 |
| AU2021357520A1 (en) | 2020-03-05 | 2022-09-29 | Neotx Therapeutics Ltd. | Methods and compositions for treating cancer with immune cells |
| US11213482B1 (en) | 2020-03-05 | 2022-01-04 | University of Pittsburgh—Of the Commonwealth System of Higher Educat | SARS-CoV-2 subunit vaccine and microneedle array delivery system |
| US11773391B2 (en) | 2020-04-01 | 2023-10-03 | University of Pittsburgh—of the Commonwealth System of Higher Education | Therapeutic and diagnostic target for SARS-CoV-2 and COVID-19 |
| EP4135757A1 (en) | 2020-04-13 | 2023-02-22 | Janssen Biotech, Inc. | Psma and steap1 vaccines and their uses |
| EP4142785A2 (en) | 2020-04-29 | 2023-03-08 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Recombinant human metapneumovirus f proteins and their use |
| WO2022009052A2 (en) | 2020-07-06 | 2022-01-13 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| WO2022009051A1 (en) | 2020-07-06 | 2022-01-13 | Janssen Biotech, Inc. | A method for determining responsiveness to prostate cancer treatment |
| US20230024133A1 (en) | 2020-07-06 | 2023-01-26 | Janssen Biotech, Inc. | Prostate Neoantigens And Their Uses |
| WO2022035860A2 (en) | 2020-08-10 | 2022-02-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Replication-competent adenovirus type 4-hiv env vaccines and their use |
| US20240228549A1 (en) | 2021-04-29 | 2024-07-11 | The U.S.A., As Represented By The Secretary, Department Of Health And Human Services | Prefusion-stabilized lassa virus glycoprotein complex and its use |
| AU2022323509A1 (en) | 2021-08-03 | 2024-02-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hiv-1 vaccination and samt-247 microbicide to prevent hiv-1 infection |
| US20230141563A1 (en) | 2021-10-12 | 2023-05-11 | Selecta Biosciences, Inc. | Methods and compositions for attenuating anti-viral transfer vector igm responses |
| US20250018060A1 (en) | 2021-11-19 | 2025-01-16 | Christiana Care Gene Editing Institute, Inc. | Adenovirus delivery system for cancer treatment |
| US20230357437A1 (en) | 2022-03-09 | 2023-11-09 | Selecta Biosciences, Inc. | Immunosuppressants in combination with anti-igm agents and related dosing |
| WO2023192835A1 (en) | 2022-03-27 | 2023-10-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Base-covered hiv-1 envelope ectodomains and their use |
| WO2023196898A1 (en) | 2022-04-07 | 2023-10-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Beta globin mimetic peptides and their use |
| EP4338727A1 (en) | 2022-09-14 | 2024-03-20 | Roquette Freres | Adenovirus formulations |
| WO2024233783A1 (en) | 2023-05-09 | 2024-11-14 | Cornell University | Expression cassette coding for vascular endothelial growth factor |
| WO2024249626A1 (en) | 2023-05-30 | 2024-12-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hiv-1 envelope triple tandem trimers and their use |
| WO2025158316A1 (en) | 2024-01-26 | 2025-07-31 | Janssen Biotech, Inc. | Ovarian neoantigens and use thereof |
| WO2026030724A1 (en) | 2024-08-01 | 2026-02-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Sars-cov-2 vaccine |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA858044B (en) * | 1984-11-01 | 1987-05-27 | American Home Prod | Oral vaccines |
| FR2705686B1 (fr) * | 1993-05-28 | 1995-08-18 | Transgene Sa | Nouveaux adénovirus défectifs et lignées de complémentation correspondantes. |
| DK0638316T3 (da) * | 1993-08-11 | 2003-09-22 | Wyeth Corp | Rekombinante adenovirusvacciner |
| US5543328A (en) * | 1993-08-13 | 1996-08-06 | Genetic Therapy, Inc. | Adenoviruses having modified fiber proteins |
| WO1996009399A2 (en) * | 1994-09-23 | 1996-03-28 | Somatix Therapy Corporation | Chimeric adenovirus for gene delivery |
-
1995
- 1995-10-02 US US08/537,402 patent/US5837511A/en not_active Expired - Lifetime
-
1996
- 1996-09-24 AT AT96935925T patent/ATE323773T1/de not_active IP Right Cessation
- 1996-09-24 DE DE69636055T patent/DE69636055T2/de not_active Revoked
- 1996-09-24 JP JP9514303A patent/JPH11514866A/ja not_active Withdrawn
- 1996-09-24 WO PCT/US1996/015274 patent/WO1997012986A2/en not_active Ceased
- 1996-09-24 EP EP96935925A patent/EP0866873B1/en not_active Revoked
-
2008
- 2008-07-09 JP JP2008179643A patent/JP2009028040A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO1997012986A2 (en) | 1997-04-10 |
| US5837511A (en) | 1998-11-17 |
| EP0866873A2 (en) | 1998-09-30 |
| ATE323773T1 (de) | 2006-05-15 |
| DE69636055D1 (de) | 2006-05-24 |
| JP2009028040A (ja) | 2009-02-12 |
| EP0866873B1 (en) | 2006-04-19 |
| WO1997012986A3 (en) | 1997-06-19 |
| JPH11514866A (ja) | 1999-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69834489T2 (de) | Methode für die produktion von adenoviralen vektoren, die nicht vom serotyp c abgeleitet sind | |
| DE69635931T2 (de) | Komplementäre adenovirenvectorsysteme und zelllinien | |
| DE69535178T2 (de) | Adenoviren-vektor systeme und zelllinien | |
| US5837511A (en) | Non-group C adenoviral vectors | |
| DE69425989T3 (de) | Neue Komplementations-Zelllinien für defekte adenovirale Vektoren | |
| DE69633565T2 (de) | Verpackungssysteme für humane rekombinante adenoviren, zur vewendung in der ge ntherapie | |
| DE69931391T2 (de) | Trans-aktivierung und cis-aktivierung um die dauer der expression eines transgens zu modulieren | |
| DE69534166T2 (de) | Rekombinanter adenovirus und methoden zu dessen verwendung | |
| DE69429260T2 (de) | Adenovirale vektoren tierischen ursprungs und ihre verwendung bei der gentherapie | |
| DE69534902T2 (de) | Rekombinanter viraler DNS Vektor zur Transfektion tierischer Zellen | |
| WO1997012986A9 (en) | Non-group c adenoviral vectors | |
| DE69535093T2 (de) | Defektive rekombinante adenoviren mit einem inaktivierten gen iv a 2 | |
| DE69838644T2 (de) | Verfahren zur herstellung eines rekombinanten rinderadenovirus-vektors | |
| AU730278B2 (en) | Complementary adenoviral vector systems and cell lines | |
| AU703768C (en) | Complementary adenoviral vector systems and cell lines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8363 | Opposition against the patent | ||
| 8331 | Complete revocation |